Has Sohail Minhas, MD received payments from drug or device companies?

Yes. Drug and device makers reported $33,616 in general payments to Sohail Minhas, MD across 863 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sohail Minhas, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sohail Minhas, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sohail Minhas, MD

Hematology & Oncology · Southaven, MSNPI 1053303750

Payments from drug & device makers

$33,616in general payments, 2019–2025

Across 863 payments — averaging $38.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$18K
Johnson & Johnson$2K
Novartis$1K
Merck$1K
E.r. Squibb & Sons, L.L.C.$1K
Pfizer$1K
plus $10K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	38	$17,633
Johnson & Johnson(2 entities)	78	$1,586
Novartis	84	$1,364
Merck	50	$1,048
E.r. Squibb & Sons, L.L.C.	75	$1,043
Pfizer	70	$1,030
Lilly USA, LLC	36	$725
Astellas Pharma US Inc	19	$710
Gilead(2 entities)	31	$618
Exelixis Inc.	26	$561
Takeda Pharmaceuticals U.S.A., Inc.	21	$530
Amgen	34	$513
Seagen Inc.	21	$486
AbbVie	23	$465
GSK	21	$428
Daiichi Sankyo Inc.	17	$411
Bristol Myers Squibb	20	$381
Eisai Inc.	20	$375
Sanofi	14	$334
Bayer	13	$254
Regeneron Healthcare Solutions, Inc.	9	$223
Tempus AI, Inc	9	$211
EMD Serono, Inc.	10	$202
Incyte Corporation	10	$200
Puma Biotechnology, Inc.	9	$163
Pharmacyclics LLC, An Abbvie Company	9	$157
Genentech USA, Inc.	9	$154
Recordati_rare_diseases_inc.	1	$152
Stemline Therapeutics Inc.	7	$150
Rigel Pharmaceuticals, Inc.	8	$141
Beone Medicines USA, Inc.	6	$114
Taiho Oncology, Inc.	6	$104
Boehringer Ingelheim	4	$84
Beigene USA, Inc.	3	$73
Genmab U.S., Inc.	3	$69
Mirati Therapeutics, Inc.	3	$69
Servier Pharmaceuticals LLC	4	$69
Array Biopharma Inc	3	$61
Coherus Oncology, Inc.	4	$61
Sumitomo Pharma America, Inc.	2	$58
AVEO Pharmaceuticals, Inc.	3	$54
Karyopharm Therapeutics Inc.	3	$47
Secura Bio, Inc.	2	$44
Biocompatibles, Inc.	2	$41
Sobi, Inc	2	$37
Springworks Therapeutics, Inc.	1	$34
Tolmar Pharmaceuticals, Inc.	2	$32
Azurity Pharmaceuticals, Inc.	1	$30
Sanofi US Services Inc.	1	$22
Blueprint Medicines Corporation	1	$21
Tesaro, Inc.	1	$20
Alnylam Pharmaceuticals Inc.	1	$20
Sun Pharmaceutical Industries Inc.	1	$19
Geron Corporation	1	$19
Jazz Pharmaceuticals Inc.	1	$19
Tersera Therapeutics LLC	1	$18
Aimmune Therapeutics, Inc.	1	$17
Apellis Pharmaceuticals, Inc.	1	$16
Pharmacosmos Therapeutics Inc.	1	$15
Clovis Oncology, Inc.	1	$14

How this compares

$33,616 in reported general payments places this provider in the 75th percentile of 57 hematology & oncology providers in Mississippi.

See all hematology & oncology providers in Mississippi →

Medicare billing

Part B allowed, 2024

$132,312

Medicare patients

410

Services billed

1,606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Southaven

Syed AzmiSouthaven$35K
Sonia BennSouthaven$26K
Muhammad MirzaSouthaven$12K
John HromHattiesburg$10M
Justin BakerJackson$2.1M
Solly ChedidPascagoula$1.7M
John HeneganJackson$1.2M
Carter MilnerJackson$261K
Andrew KellumTupelo$171K
Barbara CraftJackson$135K

See the full list for Mississippi →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →